At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 51 enrolled
Drug / intervention
Cardiac Resynchronization Therapy Defibrillatordevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
QUARTET LEAD AND RESYNCHRONIZATION THERAPY OPTIONS To Investigate the Stimulatory Possibilities Offered by the Different Configurations Available for the Quartet Lead and Their Effect on Haemodynamic and Clinical Response.
In Brief
A Phase 4 clinical trial evaluating Cardiac Resynchronization Therapy Defibrillator for Heart Failure. Completed, enrolled 51 participants across 1 site.
Detailed Summary
The purpose of this Clinical Trial is to determine the percentage of patients whose hemodynamic response improves with the different configurations offered by the new Quartet® left ventricular lead, as a result of its four electrodes, with respect to the configurations offered by a standard bipolar lead. Furthermore, the optimal stimulation configuration will be determined from a comparison with traditional configurations.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
CountriesSpain
Collaborators--
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2011
First PostedFeb 2011
Primary CompletionApr 2012
Study CompletionSep 2012
TodayJul 2026
First PostedFeb 15, 2011
Enrollment StartJan 1, 2011
Primary CompletionApr 1, 2012
Study CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 15.4 years ago
Interventions
Cardiac Resynchronization Therapy Defibrillatordevice
Cardiac Resynchronization Therapy Defibrillator